Help employers find you! Check out all the
BETHLEHEM, Pa., July 22, 2014 /PRNewswire/ -- Eyeon Therapeutics has received a Notice of Allowance on a novel dry eye treatment based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO. The product has been shown to be safe and effective in a small trial previously published. Mark Mitchnick, MD, CEO states, "This first set of claims around the polymer and its class will go a long way to moving this technology into the commercial phase. We have been using it in several development projects, and we believe it has promise in many ocular formulations as well as in other areas. Helping Eyeon gain a proprietary position in this very important market is a great example of what Particle Sciences offers its partners."
David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few therapies. Our product offers a unique approach that is clinically validated and useful in a number of ocular applications. In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered inBethlehem, Pennsylvania. Visit www.particlesciences.com, email firstname.lastname@example.org, or contact us at (610) 861- 4701 for information.
Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at email@example.com
SOURCE Particle Sciences